statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Research analysts at Wedbush lifted their Q1 2024 earnings per share estimates for shares of Sutro Biopharma in a report issued on Tuesday...

Q1 2024 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Boosted by Wedbush

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

This is a signal that STRO's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Sutro Biopharma (STRO, $5.32) RSI Indicator left the overbought zone on April 01, 2024

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a...

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Sutro Biopharma shares are trading lower by 4.3% during Tuesday's session. The company announced the pricing of an underwritten offering.
read more...

What's Going On With Sutro Biopharma (STRO) Stock?

Investors considering a purchase of Sutro Biopharma Inc (STRO) stock, but tentative about paying the going market price of 5.28/share, might benefit from considering selling puts among the...

Commit To Buy Sutro Biopharma At $2.50, Earn 12.9% Annualized Using Options

Shares of Sutro Biopharma (NASDAQ:STRO) have been up over 50% in the past few days on the strength of an earnings beat. The recent acquisition of I...

Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech Investors

Oppenheimer reaffirmed their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO - Free Report) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has...

Oppenheimer Reiterates "Outperform" Rating for Sutro Biopharma (NASDAQ:STRO)

JMP Securities reissued their market outperform rating on shares of Sutro Biopharma (NASDAQ:STRO - Free Report) in a research report report published on Tuesday morning, Benzinga reports. JMP...

JMP Securities Reaffirms "Market Outperform" Rating for Sutro Biopharma (NASDAQ:STRO)

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Stock analysts at Wedbush decreased their Q1 2024 earnings estimates for shares of Sutro Biopharma in a research report issued to clients and...

Analysts Set Expectations for Sutro Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:STRO)

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Volume	622,024.00
52-Wk High	$6.13
52-Wk Low	$2.01

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.92	--	--	N/A
Q4'23	-$0.41	$0.52	227.82%	BEAT
Q3'23	-$0.74	-$0.81	-10.05%	MISSED
Q2'23	-$0.73	-$0.64	12.63%	BEAT
Q1'23	-$0.78	-$0.85	-8.45%	MISSED

STRO Sutro Biopharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals